Establishment of a 2-D human urinary proteomic map in IgA nephropathy

Park, Mi‐Ra; Wang, Eun-Hui; Jin, Dong-Chan; Cha, Jung-Ho; Lee, Kweon-Heang; Yang, Chul-Woo; Kang, Chang-Suk; Choi, Yeong-Jin

doi:10.1002/pmic.200500023

Cited by 77 publications

(45 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…␣1-Antitrypsin was identified as a potentially upregulated biomarker; this finding was confirmed by Western blotting. More recently, Park et al (73) examined pooled urine from 13 patients with IgA nephropathy and compared the data with those from 12 normal control subjects. The authors found an array of differentially present proteins and used the data to initiate the establishment of a human urinary proteome map of IgA nephropathy.…”

Section: Identification Of "Biomarkers" For Kidney Diseasesmentioning

confidence: 99%

Advances in Urinary Proteome Analysis and Biomarker Discovery

Fliser¹,

Novák²,

Thongboonkerd³

et al. 2007

Journal of the American Society of Nephrology

256

206

View full text Add to dashboard Cite

Noninvasive diagnosis of kidney diseases and assessment of the prognosis are still challenges in clinical nephrology. Definition of biomarkers on the basis of proteome analysis, especially of the urine, has advanced recently and may provide new tools to solve those challenges. This article highlights the most promising technological approaches toward deciphering the human proteome and applications of the knowledge in clinical nephrology, with emphasis on the urinary proteome. The data in the current literature indicate that although a thorough investigation of the entire urinary proteome is still a distant goal, clinical applications are already available. Progress in the analysis of human proteome in health and disease will depend more on the standardization of data and availability of suitable bioinformatics and software solutions than on new technological advances. It is predicted that proteomics will play an important role in clinical nephrology in the very near future and that this progress will require interactive dialogue and collaboration between clinicians and analytical specialists.

show abstract

Section: Identification Of "Biomarkers" For Kidney Diseasesmentioning

confidence: 99%

Advances in Urinary Proteome Analysis and Biomarker Discovery

Fliser¹,

Novák²,

Thongboonkerd³

et al. 2007

Journal of the American Society of Nephrology

256

206

View full text Add to dashboard Cite

show abstract

“…32 Most studies have looked at the soluble urine protein fraction, focusing on the identification of potential biomarkers in renal disease and diseases of the urogenital tract. They include studies of acute kidney injury, 33,34 acute renal allograft rejection, 35-38 glomerular disease [39][40][41][42][43][44][45][46] and carcinoma of the kidney, bladder and prostate. [47][48][49] In many cases the reported biomarkers remain unidentified, although some studies have proceeded to identification of the biomarker proteins.…”

Section: Current Biomarker Candidatesmentioning

confidence: 99%

Urine proteomics: the present and future of measuring urinary protein components in disease

Barratt

Topham²

2007

Canadian Medical Association Journal

191

126

View full text Add to dashboard Cite

P roteomics is the study of protein expression in a tissue or biological fluid. Comparison of protein patterns in biological fluids between healthy individuals and patients with disease is increasingly being used both to discover biological markers of disease (biomarkers) and to identify biochemical processes important in disease pathogenesis. Although currently available tests for urine proteins measure either the total level of urine protein or the presence of a single protein species, emerging proteomic technologies allow simultaneous examination of the patterns of multiple urinary proteins and their correlation with individual diagnoses, response to treatment or prognosis. Analysis of the various protein constituents of urine may suggest novel, noninvasive diagnostic tests, therapeutic guidance, and prognostic information for patients and clinicians.In this review, we describe the current practice of urine protein testing and the emerging technologies that are being used for analysis of the urinary proteome. BackgroundNormally, the low-molecular-weight proteins and albumin that are filtered from plasma into the early tubular fluid are almost completely reabsorbed and catabolized in the proximal tubules. As a result, daily urinary protein excretion is less than 150 mg/day, of which about 10 mg is albumin. In patients with physiologic proteinuria, the proteins excreted include mucoproteins (mainly Tamm-Horsfall protein), blood-group proteins, albumin, immunoglobulins, mucopolysaccharides and very small amounts of hormones and enzymes. Historically, proteinuria of more than 150 mg/day was regarded as abnormal. However, it is now appreciated that early renal disease is often characterized by low-level albuminuria (between 30 and 300 mg/day).1 This condition is termed microalbuminuria because the concentration of albumin is below the detection limit of traditional assays. Protein or albumin excretion greater than 300 mg/day represents overt proteinuria or macroalbuminuria; at this level, the result of standard urine dipstick testing becomes positive.Pathological proteinuria can be divided into 3 categories: glomerular proteinuria, tubular proteinuria and overload proteinuria.2 Glomerular proteinuria results from an increase in the permeability of the glomerular capillary wall to macromolecules (particularly albumin) and usually results from glomerular disease. Tubular proteinuria results from reduced reabsorption of proteins that are normally present in the glomerular filtrate or from excretion of proteins derived from injured tubular epithelial cells. It is usually caused by diseases of the tubulointerstitium. Overload proteinuria is due to an excess of low-molecular-weight proteins that are normally reabsorbed by the proximal tubules. These proteins are most often immunoglobulin light chains (in the plasma cell dyscrasias), although lysozyme (in myelomonocytic leukemia), myoglobin (in rhabdomyolysis) or hemoglobin (in intravascular hemolysis) may also be identified.Under normal conditions, urinary proteins exis...

show abstract

“…In proteomic analysis of urine from patients with IgA nephropathy, the authors found an array of differentially present proteins and used the data to initiate the establishment of a human urinary proteome map of IgA nephropathy. [40] In a recent study of focal segmental glomerulosclerosis (FSGS), 37 urinary proteins were identified, showing characteristic patterns of dynamic changes along the disease course of FSGS. [41] Some urinary proteins appearing earlier than glomerular sclerosis could serve as potential early diagnostic biomarkers.…”

Section: Protein Expression Profiles In the Normal Urinementioning

confidence: 99%

Challenges of Genomics and Proteomics in Nephrology

et al. 2009

View full text Add to dashboard Cite

An increasing number of patients suffering from renal diseases and limitations in standard diagnostic and therapeutic approaches has created an intense interest in applying genomics and proteomics in the field of nephrology. Genomics has provided a vast amount of information, linking the gene activity with disease. However, proteomic technologies allow us to understand proteins and their modifications, elucidating properties of cellular behavior that may not be reflected in analysis of gene expression. The application of these innovative approaches has recently yielded the promising new urinary biomarkers for acute kidney injury and chronic kidney disease, thus providing a better insight in renal pathophysiology and establishing the basis for new therapeutic strategies. Despite significant improvements in therapeutics, the mortality and morbidity associated with acute renal failure (ARF) remain high. The lack of early markers for ARF causes an unacceptable delay in initiating therapy. These biomarker panels will probably be useful for assessing the duration and severity of ARF, and for predicting progression and adverse clinical outcomes. Kidney failure leads to the uremic syndrome characterized by accumulation of uremic toxins, which are normally cleared by the kidneys. Proteomics has gained considerable interest in this field, as a new and promising analytical approach to identify new uremic toxins. The urinary proteome as a tool for biomarker discovery is still in its early phase. A major challenge will be the integration of proteomics with genomics data and their functional interpretation in conjunction with clinical results and epidemiology.

show abstract

Establishment of a 2-D human urinary proteomic map in IgA nephropathy

Cited by 77 publications

References 27 publications

Advances in Urinary Proteome Analysis and Biomarker Discovery

Advances in Urinary Proteome Analysis and Biomarker Discovery

Urine proteomics: the present and future of measuring urinary protein components in disease

Challenges of Genomics and Proteomics in Nephrology

Contact Info

Product

Resources

About